Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Latin Times on MSN2h
UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: FedsThe UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback